Isoprenoids and Alzheimer's disease: a complex relationship

Neurobiol Dis. 2006 May;22(2):209-22. doi: 10.1016/j.nbd.2005.11.007. Epub 2006 Jan 10.

Abstract

Cholesterol metabolism has been linked to Alzheimer's disease (AD) neuropathology, which is characterized by amyloid plaques, neurofibrillary tangles and neuroinflammation. Indeed, the use of statins, which inhibit cholesterol and isoprenoid biosynthesis, as potential AD therapeutics is under investigation. Whether statins offer benefit for AD will be determined by the outcome of large, placebo-controlled, randomized clinical trials. However, their use as pharmacological tools has delineated novel roles for isoprenoids in AD. Protein isoprenylation regulates multiple cellular and molecular events and here we review the complex roles of isoprenoids in AD-relevant processes and carefully evaluate isoprenoid pathways as potential AD therapeutic targets.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / physiopathology
  • Amyloid beta-Peptides / antagonists & inhibitors
  • Amyloid beta-Peptides / biosynthesis
  • Animals
  • Brain / drug effects
  • Brain / metabolism
  • Brain / physiopathology
  • Cholesterol / biosynthesis*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Neurofibrillary Tangles / drug effects
  • Neurofibrillary Tangles / metabolism
  • Plaque, Amyloid / drug effects
  • Plaque, Amyloid / metabolism
  • Protein Prenylation / drug effects*
  • Protein Prenylation / physiology
  • Terpenes / metabolism*

Substances

  • Amyloid beta-Peptides
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Terpenes
  • Cholesterol